Restoring repolarization in LQT3

Heart Rhythm

Volumn 6, Issue 1, 2009, Pages 107-108

  George Jr , Alfred L ^a  

^a Institute for Integrative Genomics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANOLAZINE;

EDITORIAL; GENE MUTATION; GENOTYPE; HEART ARRHYTHMIA; IN VITRO STUDY; LONG QT SYNDROME; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPOLARIZATION;

ACTION POTENTIALS; ANIMALS; DISEASE MODELS, ANIMAL; GUINEA PIGS; HEART VENTRICLES; ION CHANNEL GATING; LONG QT SYNDROME; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PHENYLUREA COMPOUNDS; POTASSIUM CHANNELS; SODIUM CHANNELS; TETRAZOLES;

EID: 58049169785     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2008.10.037     Document Type: Editorial

References (13)

1. Bennett P.B., Yazawa K., Makita N., et al. Molecular mechanism for an inherited cardiac arrhythmia. Nature 376 (1995) 683-685
2. Vatta M., Ackerman M.J., Ye B., et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 114 (2006) 2104-2112
3. Medeiros-Domingo A., Kaku T., Tester D.J., et al. SCN4B-encoded sodium channel β4 subunit in congenital long-QT syndrome. Circulation 116 (2007) 134-142
4. Ueda K., Valdivia C., Medeiros-Domingo A., et al. Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. Proc Natl Acad Sci U S A 105 (2008) 9355-9360
5. Wang D.W., Yazawa K., Makita N., et al. Pharmacological targeting of long QT mutant sodium channels. J Clin Invest 99 (1997) 1714-1720
6. + channel blockade and to increases in heart rate - Implications for gene-specific therapy. Circulation 92 (1995) 3381-3386
7. Fabritz L., Kirchhof P., Franz M.R., et al. Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice. Cardiovasc Res 57 (2003) 1085-1093
8. Fredj S., Sampson K.J., Liu H., and Kass R.S. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol 148 (2006) 16-24
9. Priori S.G., Napolitano C., Schwartz P.J., et al. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation 102 (2000) 945-947
10. Ruan Y., Liu N., Bloise R., et al. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 116 (2007) 1137-1144
11. Schwartz P.J., Priori S.G., Spazzolini C., et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 103 (2001) 89-95
12. Kr activation in a cellular model of LQT3. Heart Rhythm 6 (2008) 100-106
13. Hansen R.S., Diness T.G., Christ T., et al. Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5-yl)-phenyl)-N'-(3'-trifluoromethylphenyl)urea]. Mol Pharmacol 70 (2006) 1319-1329